Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus

J Clin Invest. 1997 Aug 1;100(3):678-84. doi: 10.1172/JCI119580.

Abstract

We postulated that nitric oxide (NO)-mediated endothelial function would be improved by acute and short-term treatment with an angiotensin converting enzyme (ACE) inhibitor in patients with type I diabetes mellitus, in whom endothelial function is depressed. Nine type I diabetic patients and eight healthy subjects underwent forearm blood flow measurement using strain gauge plethysmography during intraarterial infusion of incremental doses of endothelium-dependent (acetylcholine [ACh]) and endothelium-independent (sodium nitroprusside [SNP]) vasodilators. Pretreatment ACh responses were depressed in diabetic patients relative to the normal subjects (P < 0.05). No difference between the groups was evident in response to SNP. Acute ACE inhibition (with intrabrachial enalaprilat) enhanced ACh responses in the diabetic patients (P < 0.005), with a further improvement evident after 1 mo of oral therapy with enalapril (P < 0.001) when ACh responses were normalized. ACE inhibition did not affect SNP responses. We conclude that acute administration of the ACE inhibitor, enalaprilat, enhances NO-mediated endothelial function in type I diabetic patients, with further improvement evident after 4 wk of enalapril therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 1 / physiopathology*
  • Enalapril / administration & dosage*
  • Enalaprilat / administration & dosage*
  • Endothelium / drug effects
  • Endothelium / physiopathology*
  • Humans
  • Male
  • Middle Aged
  • Nitric Oxide / physiology

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Nitric Oxide
  • Enalapril
  • Enalaprilat